Biotech Values

[DewDiligence]

Might Roche have wanted to get out of the [ITMN] exclusivity for more immediate reasons? Specifically I was wondering if they would consider some sort of marketing deal with Vertex where they push Pegasys instead of PEG-Intron.

Roche doesn’t need to ink a deal to push Pegasys instead of Pegintron because everyone (except, of course, MRK) has abandoned Pegintron already.

I still remain in the camp that Danoprevir's still alive

Other than saving face, what possible reason could Roche have to move forward with a product that’s clearly inferior to other HCV PI’s in development?